

Ovarian Endometroid Adenocarcinoma (20x)
353.2-1 [1.5µg/ml]
353.9-20 [6µg/ml]
NSCLC Adenocarcinoma (20x)
353.2-1 [1.5µg/ml]
353.9-20 [6µg/ml]

FIG. 1



Normal Salivary Gland (20x)
353.2-1, 1.5µg/ml
353.9-20, 6µg/ml
Normal Pancreas (20x)
353.2-1, 1.5µg/ml
353.9-20, 6µg/ml

FIG. 2



Clone 9.21
Clone 2.1
Clone 3.8
Clone 5.7
1 2 3 4 5 6 7 8
Cell lysates: 1 – Igrov-1; 2 – Ovcar-3; 3 – Caov-3; 4 – Wish; 5 – Skov-3;6 – BxPC3; 7 – Panc-1
8 - ASPC1

FIG. 3



2.1
3.8
5.7
9.21
Fluorescent Units
0
200
400
600
800
Antibody, [M]
10-12
10-11
10-10
10-9
10-8
10-7
10-6

FIG. 4A




2.1
3.8
5.7
9.21
Fluorescent Units
0
10
20
30
40
50
60
Antibody [M]
10-13
10-12
10-11
10-10
10-9
10-8
10-7
10-6

FIG. 4B



Clone	EC50, nM
2.1	0.5
3.8	0.7
5.7	0.9
9.21	0.7

FIG. 5



FOLR2-ELISA
anti-FOLR2 Antibody
2.1
3.8
5.7
9.21
OD 450nm
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
[Ab], M
10-12
10-11
10-10
10-9
10-8
10-7

FIG. 6A




FOLR3-ELISA
anti-FOLR3 antibody
2.1
3.8
5.7
9.21
O.D. 450nm
0.8
0.6
0.4
0.2
0.0
-0.2
10-11
10-10
10-9
10-8
10-7
[Ab], M

FIG. 6B



■ huMov19, binding to non treated FOLR1

✖ huMov19, bindnig to non treated FOLR1 incubated in deglycosylation buffer (no deglycosylation enzymes added)

□ huMov19, binding to deglycosylated FOLR1 in deglycosylation buffer

■ 2.1, binding to non treated FOLR1

✖ 2.1, binding to non treated FOLR1 incubated in deglycosylation buffer (no deglycosylation enzymes added)

□ 2.1, binding to deglycosylated FOLR1 in deglycosylation buffer

FIG. 7



Igrov-1, non-treated
Igrov-1, deglycosylated
KB, non-treated
KB, deglycosylated
39 kD
huMov19
39 kD
BN3.2 (Leica)
39 kD
2.1

FIG. 8

Resurfacing of FRIHC2-1

A

FRIHC2-1- V_L			
Kabat position	Murine residue	Human v1.0 residue	Human v1.01 residue
1	D	D	D
3	V	V	V
7	**T**	***S***	***S***
9	L	L	L
15	**I**	***L***	***L***
17	**D**	***Q***	***Q***
18	**Q**	***P***	***P***
40	P	P	P
41	G	G	G
42	K	K	K
45	**Q**	***R***	***R***
57	G	G	G
60	D	D	D
67	S	S	S
77	R	R	R
81	E	E	E
100	**G**	***Q***	***Q***
103	K	K	K
107	K	K	K
108	R	R	R
24	**K**	***R***	**K**
27	**K**	***R***	**K**

B

FRIHC2-1- V_H		
Kabat position	Murine residue	Human residue
1	Q	Q
3	Q	Q
5	**Q**	***V***
9	**P**	***A***
11	**L**	***V***
13	K	K
14	P	P
19	**R**	***K***
23	K	K
28	T	T
41	P	P
42	G	G
43	Q	Q
61	**E**	***Q***
62	K	K
64	**K**	***Q***
65	**A**	***G***
73	K	K
74	S	S
82b	S	S
84	S	S
85	E	E
105	Q	Q
112	S	S

FIG. 9

Resurfacing alignments

A

```
                1                                                          61
    muFRIHC2-1 VL   DVVLTQTPLSLPVNIGDQASISCKSSKSLLNSDGFTYLDWYLQKPGQSPQLLIYLVSNHFS
 huFRICH2-1 VLv1.0  ------S-------L-QP-----R--R----------------------R----------
huFRIHC2-1 VLv1.01  ------S-------L-QP----------------------------------R----------

               62                                                         113
    muFRIHC2-1 VL   GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSNYLPLTFGGGTKLEIKR
 huFRICH2-1 VLv1.0  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
huFRIHC2-1 VLv1.01  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
```

B

```
                1                                                          61
muFRIHC2-1 VH   QVQLQQSGPELVKPGASVRISCKASGYTFTNSYIHWVKKRPGQGLEWIGWIYPESLNTQYN
huFRIHC2-1 VH   ----V---A-V-------K-------------------------------------------

               62                                                         122
muFRIHC2-1 VH   EKFKAKATLTADKSSSTSYMQLSSLTSEDSAVYFCARRGIYYYSPYALDHWGQGASVTVSS
huFRIHC2-1 VH   Q--QG---------------------------------------------------------
```

FIG. 10

CDR-grafting of FRIHC2-1

A

FRIHC2-1- V_L			
Kabat position	Murine residue	Human (CDR-graft) v1.0 residue	Human (CDR-graft) v1.01 residue
2	V	I	I
4	L	M	M
12	P	S	S
14	N	T	T
15	I	P	P
17	D	Q	Q
18	Q	P	P
83	L	V	V
100	G	Q	Q
24	K	R	K
27	K	R	K

B

FRIHC2-1- V_H		
Kabat position	Murine residue	Human (CDR-graft) residue
5	Q	V
9	P	A
11	L	V
12	V	K
19	R	K
20	I	V
38	K	R
39	K	Q
40	R	A
48	I	M
66	K	R
67	A	V
69	L	M
71	A	R
73	K	T
75	S	I
78	S	A
81	Q	E
82b	S	R
83	T	R
85	E	D
87	S	T
91	F	Y
107	A	T
108	S	L

FIG. 11

CDR grafting alignments

A

```
                1                                                                61
      muFRIHC2-1 VL   DVVLTQTPLSLPVNIGDQASISCKSSKSLLNSDGFTYLDWYLQKPGQSPQLLIYLVSNHFS
 huFRIHC2-1 VLGv1.0   -I-M-------S-TP-QP-----R--R-------------------------------
huFRIHC2-1 VLGv1.01   -I-M-------S-TP-QP-------------------------------------------

               62                                                113
      muFRIHC2-1 VL   GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSNYLPLTFGGGTKLEIKR
 huFRIHC2-1 VLGv1.0   -------------------------V---------------Q--------
huFRIHC2-1 VLGv1.01   -------------------------V---------------Q--------
```

B

```
                1                                                                61
 muFRIHC2-1 VH   QVQLQQSGPELVKPGASVRISCKASGYTFTNSYIHWVKKRPGQGLEWIGWIYPESLNTQYN
huFRIHC2-1 VHG   ----V---A-VK------KV----------------RQA-------M-------------

               62                                                122
 muFRIHC2-1 VH   EKFKAKATLTADKSSSTSYMQLSSLTSEDSAVYFCARRGIYYYSPYALDHWGQGASVTVSS
huFRIHC2-1 VHG   -----RV-M-R-T-I--A--E--R-R-D-T---Y--------------------TL-----
```

FIG. 12





FOLR1 2.1 Antibody Titration
8µg/mL
4 µg/mL
2 µg/mL
1 µg/mL
0.5 µg/mL
0.25 µg/mL
8 µg/ml
4 µg/ml
2 µg/ml
1 µg/ml
0.5 µg/ml
0.25 µg/ml

FIG. 13




Fallopian Tube Positive

FIG. 14A




FOLR1 Transfected Cells Positive

FIG. 14B




Non-Transfected Cells Unstained

FIG. 14C



Ovarian Cancer

FIG. 15A



Adenocarcinoma of the Lung

FIG. 15B




FIG. 16




FIG. 17